Invivo anti-mouse PD-1 Recombinant mAb (S-R496)

產(chǎn)品型號(hào)：S0B1459

更新時(shí)間：2025-07-01

廠商性質(zhì)：生產(chǎn)廠家

訪問量：68

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

IHC腫瘤標(biāo)志物 | 常見前列腺癌診斷

TDP-43與漸凍癥：守護(hù)or背叛？

大鼠免疫球蛋白的結(jié)構(gòu)與功能研究

基因治療中重要的AAV抗體

產(chǎn)品介紹

This antibody recognizes the same epitope as clone 29F.1A12. Programmed cell death protein 1 （PD-1）, also known as CD279, is a type I transmembrane protein and a member of the CD28 immunoglobulin superfamily. It is primarily expressed on the surface of various immune cells, including T cells, B cells, macrophages, dendritic cells, and natural killer cells. PD-1 plays a crucial role in regulating immune responses by binding to its ligands, PD-L1 （B7-H1） and PD-L2 （B7-DC）, which are expressed on antigen-presenting cells and tumor cells. When PD-1 interacts with its ligands, it triggers inhibitory signals that downregulate T cell activity, preventing excessive immune responses and promoting self-tolerance. However, this pathway can also be exploited by cancer cells to evade immune surveillance, leading to tumor progression. As a result, PD-1 has become a key target in cancer immunotherapy, with several anti-PD-1 antibodies approved for treating various cancers, achieving significant and durable efficacy in some patients.

上一個(gè)：S0B1841BrdU Recombinant Mouse mAb (FITC Conjugate) (S-R639)